Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1, SI-B003, and BL-B01D1 + SI-B003 in recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors
CTR20232556Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in head and neck squamous cell carcinoma (HNSCC), Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Started Nov 2023; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232556.